Cogent Biosciences (COGT) vs Rhythm Pharmaceuticals (RYTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cogent Biosciences (COGT) has outperformed Rhythm Pharmaceuticals (RYTM) over the past year, gaining 95.2% versus a loss of 11.4%. Over five years, RYTM leads with a +682.1% price change compared with +226.2% for COGT. Rhythm Pharmaceuticals is the larger company by market cap ($6.18 billion vs $5.22 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COGT | RYTM |
|---|---|---|
| Share price | $30.07 | $89.73 |
| Market cap | $5.22B | $6.18B |
| 1-day change | -0.25% | +1.45% |
| YTD return | -15.15% | -17.37% |
| 1-year return | +95.21% | -11.40% |
| 5-year return | +226.19% | +682.05% |
| EPS (TTM) | $-2.16 | $-3.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $189.76M |
| Revenue growth (YoY) | — | +45.83% |
| Net income (latest FY) | $-328.94M | $-196.54M |
| Gross margin | — | 89.73% |
| Operating margin | — | -101.19% |
| Net margin | — | -103.57% |
| 52-week high | $43.73 | $122.20 |
| 52-week low | $13.78 | $74.50 |
| Distance from 52-week high | -31.25% | -26.57% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +85.66% | +54.45% |
| Average volume | 1.90M | 649.06K |
| Shares outstanding | 173.52M | 68.85M |
| Employees | 258 | 414 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COGT has outperformed RYTM by 106.6 percentage points over the past year.
About Cogent Biosciences
COGT stock →Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
About Rhythm Pharmaceuticals
RYTM stock →Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees
COGT vs RYTM FAQ
Which is bigger, Cogent Biosciences or Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals (RYTM) is larger, with a market capitalization of $6.18B compared with $5.22B for Cogent Biosciences (COGT).
Which stock has performed better over the past year, COGT or RYTM?
COGT returned +95.21% over the past 12 months, compared with -11.40% for RYTM (price return, excluding dividends). Past performance does not predict future results.
Are Cogent Biosciences and Rhythm Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.